Translating Science into Clinical Success
Independent expertise in immuno-oncology, translational medicine and biomarker development
Connecting the Dots Others Don't See
Many development programmes generate data. Far fewer generate understanding.
How I Support Biotechnology Companies
Translational Strategy • Biomarker Strategy • Early Clinical Development • CRO & Vendor Oversight • Assay Strategy • Data-Driven Decision Support
Many development programmes generate large volumes of data. Far fewer generate true understanding.
I help teams connect disease biology, drug mechanism, patient heterogeneity and clinical outcomes into a coherent translational strategy.
My strength lies in recognising patterns, identifying missing links, and uncovering opportunities that may be overlooked when scientific disciplines operate in isolation.
By integrating evidence from pathology, immunology, flow cytometry, multi-omics and clinical data, I help organisations understand not only what is happening, but why it is happening. This approach enables the identification of mechanisms of response and resistance, patient stratification opportunities, and translational insights that support confident clinical decision-making.
I am known for asking unconventional questions and challenging assumptions that may otherwise go untested. Often, the most valuable insight is not found in the data itself, but in recognising what has not yet been explored.
The most valuable answers often come from the questions nobody thought to ask.
Selected Project Experience
First-in-Human Biomarker Strategy
Clinical Immunomonitoring & Translational Biomarkers
Clinical Immunomonitoring & Translational Biomarkers
Integrated translational biomarker strategy linking preclinical evidence, clinical sampling, immune monitoring and data capture.
Clinical Immunomonitoring & Translational Biomarkers
Clinical Immunomonitoring & Translational Biomarkers
Clinical Immunomonitoring & Translational Biomarkers
Experience spanning solid tumours and haematological malignancies, including melanoma, NSCLC, bladder cancer, AML, lymphomas and multiple myeloma, across therapeutic modalities ranging from cell therapies and microbial immunotherapies to immune checkpoint inhibitors, targeted protein degraders and combination approaches..
Clinical Trial Readiness
Clinical Immunomonitoring & Translational Biomarkers
Clinical Trial Readiness
Established laboratory operations, sample-management processes and CRO governance supporting oncology study execution.
Programme Leadership
Translational Data Infrastructure
Clinical Trial Readiness
Coordinated cross-functional translational, preclinical, discovery and CMC activities supporting drug development.
Translational Data Infrastructure
Translational Data Infrastructure
Translational Data Infrastructure
Connected biospecimen management, CRO workflows, analytical data and patient-level reporting.
Biomarker Vendor Governance
Translational Data Infrastructure
Translational Data Infrastructure
Built GxP-compliant frameworks for analytical vendor qualification, selection and oversight.
Oncology & Therapeutic Experience
Therapeutic Modalities
✅ Cell Therapies
✅ Microbial Therapies
✅ Targeted Protein Degraders
✅ Immune Checkpoint Inhibitors
✅ Combination Therapies
Disease Areas
AML • MDS • Lymphoma • Multiple Myeloma
• Melanoma • NSCLC • NMIBC • HCC • PDAC • Breast Cancer • Ovarian Cancer • Synovial Sarcoma